RCKT
Price
$5.81
Change
-$0.86 (-12.89%)
Updated
Apr 1 closing price
Capitalization
619.52M
40 days until earnings call
RYTM
Price
$50.00
Change
-$2.97 (-5.61%)
Updated
Apr 1 closing price
Capitalization
3.16B
34 days until earnings call
Ad is loading...

RCKT vs RYTM

Header iconRCKT vs RYTM Comparison
Open Charts RCKT vs RYTMBanner chart's image
Rocket Pharmaceuticals
Price$5.81
Change-$0.86 (-12.89%)
Volume$7.73M
Capitalization619.52M
Rhythm Pharmaceuticals
Price$50.00
Change-$2.97 (-5.61%)
Volume$653.2K
Capitalization3.16B
RCKT vs RYTM Comparison Chart
Loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCKT vs. RYTM commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCKT is a StrongBuy and RYTM is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (RCKT: $6.67 vs. RYTM: $52.97)
Brand notoriety: RCKT and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCKT: 420% vs. RYTM: 126%
Market capitalization -- RCKT: $619.52M vs. RYTM: $3.16B
RCKT [@Biotechnology] is valued at $619.52M. RYTM’s [@Biotechnology] market capitalization is $3.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCKT’s FA Score shows that 1 FA rating(s) are green whileRYTM’s FA Score has 0 green FA rating(s).

  • RCKT’s FA Score: 1 green, 4 red.
  • RYTM’s FA Score: 0 green, 5 red.
According to our system of comparison, RYTM is a better buy in the long-term than RCKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCKT’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 5 bullish TA indicator(s).

  • RCKT’s TA Score: 4 bullish, 4 bearish.
  • RYTM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RYTM is a better buy in the short-term than RCKT.

Price Growth

RCKT (@Biotechnology) experienced а -23.60% price change this week, while RYTM (@Biotechnology) price change was -1.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

RCKT is expected to report earnings on May 12, 2025.

RYTM is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($3.16B) has a higher market cap than RCKT($620M). RYTM YTD gains are higher at: -5.377 vs. RCKT (-46.937). RYTM (-238.09M) and RCKT (-247.48M) have comparable annual earnings (EBITDA) . RCKT has more cash in the bank: 372M vs. RYTM (321M). RYTM has less debt than RCKT: RYTM (3.94M) vs RCKT (25.5M). RYTM has higher revenues than RCKT: RYTM (130M) vs RCKT (0).
RCKTRYTMRCKT / RYTM
Capitalization620M3.16B20%
EBITDA-247.48M-238.09M104%
Gain YTD-46.937-5.377873%
P/E RatioN/AN/A-
Revenue0130M-
Total Cash372M321M116%
Total Debt25.5M3.94M648%
FUNDAMENTALS RATINGS
RCKT vs RYTM: Fundamental Ratings
RCKT
RYTM
OUTLOOK RATING
1..100
710
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
96
Overvalued
PROFIT vs RISK RATING
1..100
10037
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9347
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (29) in the Biotechnology industry is significantly better than the same rating for RYTM (96). This means that RCKT’s stock grew significantly faster than RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for RCKT (100). This means that RYTM’s stock grew somewhat faster than RCKT’s over the last 12 months.

RCKT's SMR Rating (97) in the Biotechnology industry is in the same range as RYTM (100). This means that RCKT’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for RCKT (93). This means that RYTM’s stock grew somewhat faster than RCKT’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RCKT (100). This means that RYTM’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCKTRYTM
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 16 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 12 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 7 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRIEX13.11N/A
N/A
Meridian Hedged Equity Investor
JMCVX15.20N/A
N/A
Janus Henderson Mid Cap Value T
NMULX9.96N/A
N/A
Neuberger Berman Multi-Cap Opp I
TASHX14.29N/A
N/A
Transamerica Multi-Asset Income A
MDIIX16.34-0.16
-0.97%
iShares MSCI EAFE Intl Idx Inv A